Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Bleeding Dieulafoy lesions of the small bowel: a systematic study on the epidemiology and efficacy of enteroscopic treatment.

Dulic-Lakovic E, Dulic M, Hubner D, Fuchssteiner H, Pachofszky T, Stadler B, Maieron A, Schwaighofer H, Püspök A, Haas T, Gahbauer G, Datz C, Ordubadi P, Holzäpfel A, Gschwantler M; Austrian Dieulafoy-bleeding Study Group.

Gastrointest Endosc. 2011 Sep;74(3):573-80. doi: 10.1016/j.gie.2011.05.027. Epub 2011 Jul 29.

PMID:
21802676
2.

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.

Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P; Austrian Hepatitis Study Group.

Gastroenterology. 2010 Feb;138(2):503-12, 512.e1. doi: 10.1053/j.gastro.2009.10.058. Epub 2009 Nov 10.

PMID:
19909752
3.

Peginterferon plus ribavirin over two years may be successful in patients with chronic hepatitis C and a very slow virologic response.

Ordubadi P, Gschwantler M.

Scand J Gastroenterol. 2009;44(9):1150-1. doi: 10.1080/00365520903104434. No abstract available.

PMID:
19593689
4.

Capsule endoscopy with retention of the capsule in a duodenal diverticulum.

Ordubadi P, Blaha B, Schmid A, Krampla W, Hinterberger W, Gschwantler M.

Endoscopy. 2008 Sep;40 Suppl 2:E247-8. doi: 10.1055/s-2008-1077563. Epub 2008 Nov 7. No abstract available.

PMID:
18991223
5.

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.

Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P; Austrian Hepatitis Study Group.

Gastroenterology. 2008 Aug;135(2):451-8. doi: 10.1053/j.gastro.2008.04.015. Epub 2008 May 27.

PMID:
18503773
6.

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K; Austrian Hepatitis Study Group.

Hepatology. 2008 Jun;47(6):1816-23. doi: 10.1002/hep.22262.

PMID:
18454510

Supplemental Content

Loading ...
Support Center